Grinu Mathew

This study identifies mTOR signaling as a therapeutic target in AXL-deficient advanced prostate cancer through kinase inhibitor screening and functional analysis.

This study uses an immunocompetent mouse model to show that Degarelix-induced chemical castration suppresses prostate cancer tumor growth initially but leads to acquired resistance over time.

This paper establishes patient-derived models of neuroendocrine prostate cancer (NEPC) from metastases, showing they retain tumor heterogeneity and can model metastatic progression.

SAKE identifies markers of resistance to BRAF inhibitors in melanoma cells by analyzing scRNA-Seq data from multiple platforms.